{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:33:28Z","timestamp":1779910408968,"version":"3.53.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02829-0","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T08:02:06Z","timestamp":1708761726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An approach to diagnosis and management of patients with pyoderma gangrenosum from an international perspective: results from an expert forum"],"prefix":"10.1007","volume":"316","author":[{"given":"Olivia M.","family":"Haddadin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Denis P.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Dissemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Shavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh A.","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"issue":"3","key":"2829_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.12788\/cutis.0076","volume":"106","author":"L Afifi","year":"2020","unstructured":"Afifi L, Ortega-Loayza AG, Shinkai K (2020) Management of classic ulcerative pyoderma gangrenosum. Cutis 106(3):119\u2013123. https:\/\/doi.org\/10.12788\/cutis.0076","journal-title":"Cutis"},{"issue":"3","key":"2829_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","volume":"18","author":"A Alavi","year":"2017","unstructured":"Alavi A, French LE, Davis MD, Brassard A, Kirsner RS (2017) Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol 18(3):355\u2013372. https:\/\/doi.org\/10.1007\/s40257-017-0251-7","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"2829_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","volume":"83","author":"J Dissemond","year":"2023","unstructured":"Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG (2023) Pyoderma gangrenosum: treatment options. Drugs 83(14):1255\u20131267. https:\/\/doi.org\/10.1007\/s40265-023-01931-3","journal-title":"Drugs"},{"issue":"4","key":"2829_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jaad.2018.08.068","volume":"80","author":"E Maverakis","year":"2019","unstructured":"Maverakis E, Le ST, Callen J, Wollina U, Marzano AV, Wallach D, Schadt C, Martinez-Alvarado YC, Cheng MY, Ma C, Merleev A, Ormerod A, Craig F, Jockenh\u00f6fer F, Dissemond J, Salva K, Williams HC, Fiorentino D (2019) New validated diagnostic criteria for pyoderma gangrenosum. J Am Acad Dermatol 80(4):87\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.068","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2829_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/bjd\/ljac137","volume":"188","author":"MA Pimentel","year":"2023","unstructured":"Pimentel MA, Li MM, Noe MH, Latour E, Seminario-Vidal L, Greiling T, Shinkai K, Hamilton A, Alavi A, Bolognia JL, Cowen EW, Dominguez A, Fernandez AP, Fivenson D, Huang WW, Madigan LM, Mauskar M, Means AD, Nelson CA, Patsatsi A, Ortega-Loayza AG (2023) Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US medical dermatology society. Br J Dermatol 188(4):566\u2013568. https:\/\/doi.org\/10.1093\/bjd\/ljac137","journal-title":"Br J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02829-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02829-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02829-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T17:02:50Z","timestamp":1710176570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02829-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2829"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02829-0","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AGOL is the current President of the Pacific Dermatology Association and serves as an associate editor for Dermatology (Karger). Additionally, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim and Janssen. Dr. Ortega has received research grants from the Lilly, Janssen, Incyte and Pfizer. He is supported by NIH NIAMS R01 AR083110. AVM reports consultancy\/advisory boards disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi, Janssen and UCB. VD reports consultancy with Abbvie, Novartis, Eli Lilly, Almirall, UCB, Sanofi, Jansenn. JD reports consultancy\/advisory boards disease-relevant honoraria from Boehringer-Ingelheim, InflaRx, Novartis, Janssen and UCB. AAN declares being a consultant and advisor and\/or receiving speaking fees\/grants and\/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi, Serono and UCB. YT reports research grants, honoraria from Eisai, Abbvie and Novartis. AA is the board member of HS foundation and a consultant for Abbvie, Almirall, BI, Kymera, InflaRx, Incyte, Novartis, UCB. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"AGOL is the current President of the Pacific Dermatology Association and serves as an associate editor for <i>Dermatology (Karger)<\/i>. In addition, he is a consultant for Genentech and Guidepoint and an advisor to Bristol Meyer Squibb, Boehringer Ingelheim and Janssen. Dr. Ortega has received research grants from the Lilly, Janssen, Incyte, and Pfizer. He is supported by NIH NIAMS R01 AR083110. AVM reports consultancy\/advisory boards disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi, Janssen and UCB. VD reports consultancy with Abbvie, Novartis, Eli Lilly, Almirall, UCB, Sanofi, Jansenn. JD reports consultancy\/advisory boards disease-relevant honoraria from Boehringer Ingelheim, InflaRx, Novartis, Janssen, and UCB. AAN declares being a consultant and advisor and\/or receiving speaking fees\/grants and\/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi, Serono, and UCB. YT reports research grants, honoraria from Eisai, Abbvie and Novartis. AA is the board member of HS foundation and a consultant for Abbvie, Almirall, BI, Kymera, InflaRx, Incyte, Novartis, UCB. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"89"}}